The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia

CNS Drugs
A George Awad, Lakshmi N P Voruganti

Abstract

Over the past two decades there has been increasing interest in including patients' self-reports in the management of their illness. Among the many reasons for such recent interest has been a rising consumer movement over the past few decades, which has led patients, their caregivers and their families to press for more meaningful sharing with physicians in the clinical decision-making process, with the clear expectations of better therapies and improved outcomes. Patients as consumers of services, their views, attitudes towards healthcare, as well as their level of satisfaction with care, have become increasingly recognized. The recent interest by the US Food and Drug Administration (FDA), as well as other regulatory agencies, in patient-reported outcomes (PROs) in the process of developing and testing new antipsychotics, has also added more impetus. It is clear that including patients in the decision-making process about the management of their psychiatric conditions also broadens the concept of 'recovery', by empowering patients to be active participants and gives a clear message that successful treatment in schizophrenia is more than a symptomatic improvement, but also includes improved functional status. Additionally, the ...Continue Reading

References

Dec 9, 2014·Schizophrenia Research and Treatment·Youssef KouidratGwenole Loas
Aug 21, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·A George Awad
Jul 26, 2015·Psychiatry Research·Karen P HayhurstShôn W Lewis
Jul 22, 2014·Journal of Korean Medical Science·Chi-Un Pae
May 21, 2016·Pharmacological Reports : PR·Rafał R JaeschkeWojciech Datka
Sep 26, 2017·Current Medical Research and Opinion·Kathleen BeusterienJohn F P Bridges
Jun 30, 2018·European Psychiatry : the Journal of the Association of European Psychiatrists·Francesco PietriniAndrea Ballerini
Oct 24, 2018·Social Psychiatry and Psychiatric Epidemiology·Nao Shiraishi, Jacqueline Reilly

Citations

Jan 1, 1985·Progress in Neuro-psychopharmacology & Biological Psychiatry·A George Awad, T P Hogan
Feb 1, 1981·Archives of General Psychiatry·T Van PuttenL A Wittmann
Jan 1, 1993·Schizophrenia Bulletin·A George Awad
May 5, 2000·The Cochrane Database of Systematic Reviews·Arja TuunainenSimon Gilbody
Sep 19, 2000·Schizophrenia Bulletin·A George Awad, Lakshmi N P Voruganti
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lakshmi N P VorugantiA George Awad
Dec 3, 2003·Psychopharmacology·Lakshmi N P Voruganti, A George Awad
Apr 30, 2004·CNS Spectrums·Antony LoebelSteven Romano
Nov 4, 2004·CNS Drugs·A George Awad, Lakshmi N P Voruganti
Oct 4, 2005·The American Journal of Psychiatry·Alan BreierJohn M Kane
Dec 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Robert A RosenheckJeffrey A Lieberman
Nov 10, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Charalampos I MitsonisMaria Nefeli E Katsanou
Dec 5, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·Duerten KudlaDieter Naber
Dec 8, 2006·The American Journal of Psychiatry·Robert A RosenheckCATIE Study Investigators
Jan 20, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C ArangoZIS Study Group
Feb 27, 2008·Psychological Bulletin·Erika A PatallJorgianne Civey Robinson
Apr 22, 2008·European Psychiatry : the Journal of the Association of European Psychiatrists·David TaylorRonald N Marcus
Oct 15, 2008·Current Opinion in Psychiatry·Georg Juckel, Pier Luigi Morosini
Oct 16, 2008·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Ariane K Kawata, Dennis A Revicki
May 8, 2009·The International Journal of Neuropsychopharmacology·Steven G PotkinCynthia O Siu
Sep 12, 2009·Journal of Clinical Psychopharmacology·Hiroyuki KobayashiMasafumi Mizuno
Aug 1, 2002·Expert Review of Pharmacoeconomics & Outcomes Research·Michael Ritsner, Rena Kurs
Feb 4, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·A George Awad

Related Concepts

Antipsychotic Effect
Schizophrenia
Impacted Tooth
Paliperidone
Ziprasidone
Lurasidone
Aripiprazole
Antipsychotic Agents
Patient Participation
Individualized Medicine

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
R P FingerF G Holz
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
Nicolas WillietLaurent Peyrin-Biroulet
© 2020 Meta ULC. All rights reserved